Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENOVA: Eplerenone in Stage 1 Hypertension
NCT04746495Phase 4Withdrawn
- Sponsor
- University of Michigan
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of eplerenone in hypertension (HTN), sponsored by University of Michigan. Planned start Feb 2023; status: withdrawn.
02
Drugs
eplerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04746495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746495.